Rocatinlimab Met Co-Primary Endpoints of vIGA-ADTM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints HORIZON is the First of Eight Phase 3 Trials in the ROCKET Program TOKYO, Sept. 25, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor. HORIZON met its co-primary endpoints: achievemen ...

One oral presentation and nine posters will shed light on real-world experiences of people living with XLH and the impact of burosumab treatment TOKYO, Sept. 19, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151) will share new research that enhances understanding about the use of burosumab in real-world clinical practice as well as the burden of those living with X-linked hypophosphatemia (XLH), a rare genetic metabolic bone disease. The findings will be presented at the American Society fo ...

PRINCETON, N.J., Aug. 23, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, is announcing that it will no longer distribute or fulfill orders for Fareston (toremefine) 60 mg tablets in the United States, effective August 31, 2024. This decision aligns with the company's Vision for 2030 and its focus on the discovery, development and delivery of novel therapies for patients. Kyowa Kirin has previou ...

Investors looking for stocks in the Beverages - Alcohol sector might want to consider either Kirin Holdings Co. (KNBWY) or Diageo (DEO) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong ...

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share pri ...

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and ...

A key driver of the new manufacturing facility is the growing global imperative to treat diseases that individually are rare, but which collectively affect an estimated 263 to 446 million people worldwide.1 Kyowa Kirin is uniquely positioned to fulfill the unmet needs of patients living with rare and underserved diseases by continuing to build on its more than 70-year history of discovering and developing novel medicines that offer life-changing value to patients. The Sanford facility will round out and enh ...

Kirin Holdings Co. (KNBWY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The ...

Kirin Group Financial Results for 3Q FY2022 November 9, 2022 Kirin Holdings Company, Limited Summary of 3Q FY2022 Results 3Q FY2022 Results > Consolidated Revenue increased by +9.8% YoY and consolidated Normalized operating profit (OP) increased by +14.5% YoY, mainly due to the recovery of the on-premise channels in the alcoholic beverages business and the impact of foreign exchange rates. > Profit before tax increased by +103.6%, mainly due to the gain from the sale of China Resources Kirin Beverages. > Pr ...

Results Presentation Fiscal 2022 First Quarter 協和キリン株式会社 Agenda | --- | --- | |------------------------------------------------------------------------------|---------------------------------------------------| | | | | Financial Review | | | Managing Executive Officer, Head of Finance | Motohiko Kawaguchi | | Commercial Update | | | Executive Officer, Head of Global Product Strategy, Strategy Division | Tomohiro Sudo | | R&D Update | | | Executive Officer, Head of R&D News Flow in 2022 | Yoshifumi Torii, Ph ...